Introduction 63
were derived from volunteers who were carefully screened. Each was thoroughly interviewed, had undergone a 116 questionnaire using the Donor History Questionnaire (DHQ) used in screening blood donors, and had received 117 laboratory testing of blood and stool according to FDA guidelines provided for donors of human cells, [28] tissues, and 118 cellular and tissue-based products (HCT/Ps) and recommendations by the Fecal Microbiota Transplant 119
Workgroup. [29] All tests are outsourced to third party Clinical Laboratory Improvement Amendments (CLIA) 120 certified testing facilities. In addition, OpenBiome provided 16S rRNA sequencing data for donor stool samples, from 121 which two donors were selected that harbored microbial signatures with low abundance of Proteobacteria and high 122 abundance of Bacteroidetes, with these two taxa being specifically examined due to prior studies linking their 123 abundance to HIV infection. 124
125

Study visits 126
Study visits were scheduled for each participant before (weeks -4, -2), at the time of (week 0), and after FMT (weeks 127 1, 2, 4, 8, 24). During each visit, stool and blood were collected, processed, and banked. Peripheral blood mononuclear 128 cells (PBMCs) were separated from blood plasma and cryopreserved while stool was immedieately stored at -80°C. 129
Control participants provided stool samples prior to colonoscopy and at weeks 1 and 8 following colonoscopy. 130
131
Study Procedure 132
Donor fecal material (FMP250, OpenBiome, Somerville, MA) was stored at -20°C and thawed before use, according 133 to protocol.
[30] Participants underwent standard bowel purge (Golytely) the day preceding FMT and the 250 mL stool 134 suspension was introduced via colonoscopy and delivered into the ileum, cecum, and ascending colon. HIV-infected 135 ART-treated control participants underwent standard bowel purge the preceding day and then colonoscopy, but did not 136 receive the donor stool suspension. 137
138
Study Measurements 139
Microbiota Analysis 140 Original Manuscript, sent for review to Journal of Infectious Diseases
Microbiota profiling was performed on samples from donors, each FMT recipient, and control subjects. DNA was 141 extracted using a protocol optimized for the isolation of bacterial DNA from feces [31] . Universal 16S rRNA primers 142 that target the V4 hypervariable region and bear unique dual-indexed barcode oligonucleotide sequences [32] were 143 utilized with the Illumina MiSeq platform to generate >92,000 high-quality paired-end 16S rRNA reads/sample. 144 QIIME software [33] was used to process 16S sequencing data and to collapse reads with 97% sequence similarity into 145 discrete operational taxonomic units (OTUs) for microbial community analyses using the Greengenes 13_5 database. 146
The same process was employed to analyze publically available stool microbiome profiling data from CDI subjects 147 before and after FMT [34] . The referenced study utilized the same primers targeting the V4 region of 16S rRNA, 148 making it highly comparable to the present study. For analyses incorporating CDI data from the referenced study, 149 sample data from these samples and the current study were concatenated prior to undergoing quality filtration and 150 OTU picking as described above. Sample community profiles were rarefied to 10,000 reads per sample. 151
An unweighted UniFrac distance matrix [35] , which considers phylogenetic similarity of microbial communities but 152 not taxon relative abundances in the calculation of between-sample ecological distances, was constructed in QIIME to 153 compare the microbiome of FMT recipients over time to those of the donor sample.
[36] This permitted assessment of 154 whether engraftment of the donor microbiome is associated with a phylogenetic shift in microbiota composition. For 155 each subject, the pairwise distance between three replicates of the donor microbiota profile (donor replicate samples 156 obtained at each FMT procedure event) and those of the recipient patient at all time points was calculated. Mean 157 distances were tested using a linear mixed effects model to assess whether significant differences in community 158 composition existed before and after FMT. Numbers of shared OTUs between donors and recipients were also tested 159 for significance using linear mixed effects models. Control subjects who provided stool samples pre-and post-160 colonoscopy were examined for changes in the microbiota that occur over time and changes that would be attributable 161 to the laxative (e.g., Golytely). 162
The permutational multivariate analysis of variance (PERMANOVA) approach[37] designed for ecological β-diversity 163 distance matrices (generated using the weighted UniFrac distance metric) and implemented in the R package 'adonis' 164 was used to test significance of differences in microbial communities based on subject groups. 165
Peripheral Blood Assays 166
Original Manuscript, sent for review to Journal of Infectious Diseases
Plasma kynurenine to tryptophan ratios were measured using high performance liquid chromatography/mass 167 spectroscopy (LC/MS), and levels of the innate immune activation marker IL-6 or sCD14 using standard ELISA kits, 168 as per established methods. [ 
3] 169
The level of T cell activation and immunophenotyping were measured by flow cytometry. Frozen PBMCs were 170 thawed and counted for batched analysis. Two million cells per sample were stained as follows: CD3-BV650 (SK7, 171 BD Biosciences, San Jose, CA), CD4-BV711 (OKT4, BioLegend, San Diego, CA), CD8α-APC-R700 (RPA-T8, BD), 172 CD45RA-APC-Cy7 (HI100, BioLegend), CCR7-BV785 (G043H7, BioLegend), CD27-BV570 (O323, BioLegend), 173
HLA-DR-PE-Cy7 (G46-6, BD), CD38-FITC (HIT2), TCR Vα7.2-BV421 (3C10. A viability dye (eF506, Affymetrix, 174 Santa Clara, CA) and dump gates (CD14-BV510 M5E2, CD19-BV510 HIB19, BioLegend) were used, and samples 175 were fixed using 1% paraformaldehyde in phosphate buffered saline. Gating for positive populations were established 176 based on FMO (fluorescence minus one) controls. Flow cytometry was done using an LSRII (BD) and data were 177 analyzed using FlowJo 10.1 (Treestar, Ashland, OR). Statistical tests were completed using linear mixed effects 178 modeling to account for the longitudinal study design and intra-individual co-variance, as implemented in the R 179 package 'lme4'. 180
Regulatory approval 181
The proposal was been approved by the FDA (IND #: 15926) and UCSF IRB (13-12675), and registered at 182 ClinicalTrials.gov (NCT02256592). The safety monitoring board comprised of clinical trial investigators met regularly 183 for this study. 184
185
Results
186
Participant Characteristics 187
Nine individuals were screened and six were enrolled for FMT ( Figure 1 ). All enrolled FMT participants were men, 188 with a median age of 61 (range 31-72), a median CD4+ T cell count of 431 (range 357-835), and a median CD4 to 189 CD8 ratio of 0.44 (range 0.33-1.36, see Table 1 Figure 1a and 1b) , which is consistent with prior reports comparing the HIV-infected gut 199 microbiota to uninfected subjects [6] [7] [8] [9] [10] [11] [12] [13] . Bacterial community sequence analyses were performed using quantifications of beta diversity, which assess 203 compositional differences between pairs of ecological communities. The unweighted UniFrac beta diversity metric, 204 which measures similarity among communities by examining phylogenetic relationships of taxa within both samples, 205 was selected for analyses, as it performed best in classifying donor replicates as belonging to their respective grouping 206 via the PERMANOVA test (Supplemental Table 1 ). Unweighted UniFrac distances between the paired donor 207 microbiota and each recipient microbiota profile generated from samples collected pre-and post-FMT were calculated. 208
The calculated UniFrac distance between donor and recipient pairs decreased following FMT, indicating that that the 209 fecal microbiota of FMT recipients became significantly more similar to that of the donor (Figure 2A ). In comparison, 210 control subjects who underwent bowel lavage and colonoscopy alone showed no significant change with respect to 211 their microbial compositional similarity to that of the donor microbial community. The compositional relatedness 212 between donors and recipients were most significant at weeks 2 and 4 (P<0.01) following FMT and less so at week 8 213 (P=0.04). Canberra beta diversity distances, which measure community similarity by examining numbers of shared 214 taxa between samples, were also calculated and similarly exhibited significant shift toward donor profiles after FMT 215 (Supplemental Figure 2) . Furthermore, proportions of shared OTUs between donor and recipient microbiota profiles 216 also increased following FMT (P=0.0019, Figure 2B ). To understand which specific bacterial taxa contributed to this 217 increase in similarity with the donors, we examined differences in all microbial genera before and after FMT. No 218 changes were significant in this small cohort following adjustment for false discovery rates (Supplemental Table 3 ). 219
However, nominal increases in Faecalibacterium and Rikenellaceae, and decreases in Erysipelotrichaceae were 220 As CDI is the main current indication for which FMT is performed clinically, we compared levels of engraftment in 233 that state in a prior study[34] to our current pilot trial in HIV-infected subjects. Significantly greater compositional 234 shift in affected CDI recipients toward the donor community was observed as compared to HIV-infected subjects using 235 unweighted UniFrac beta diversity distances as utilized above ( Figure 4B ). Furthermore, a significant increase in alpha 236 diversity (defined as numbers of observed unique taxa and their evenness of abundance distribution) was seen in CDI 237 subjects after FMT, which was not observed in our HIV-infected subjects post-FMT ( Figure 4C ). Principal coordinates 238 ordination also revealed a more dramatic shift toward donor profiles for CDI subjects than for HIV-infected subjects 239
undergoing FMT (Figures 4D). 240 241
Markers of HIV-associated inflammation remain stable after FMT 242
Markers of immune activation were assessed across time, and no trends were evident in changes in the expression of 243 the activation markers CD38 and HLA-DR on CD8+ T cells, activity of the inflammation-associated indoleamine 2,3-244 dioxygenase pathway as measured by plasma ratios of kynurenine to tryptophan, or in plasma levels of the innate 245 immune activation marker IL-6 or sCD14 (Supplemental Figure 3) . A nominal decrease in expression of the immune 246 exhaustion-associated marker PD-1 on CD8+ T cells was observed though this did not meet statistical significance 247 (P=0.07, Benjamini-Hochberg false discovery rate Q=0.29, Supplemental Figure 3 ).
Discussion 250
Ongoing inflammation and immune activation persist in HIV-infected subjects despite optimal antiretroviral therapy, 251 and markers of this inflammation remain amongst the strongest predictors of morbidity and mortality in treated HIV-252 infected subjects [14, 38] . Accordingly, identification of the etiology of this inflammation as well as development of 253 novel strategies to mitigate inflammation are a high biomedical priority. Our prior work established a novel link 254 between the altered gut microbiome in treated HIV infection and systemic markers of inflammation including the 255 kynurenine pathway.
[6] Whether the gut microbiota causally contributes to chronic inflammation in treated HIV 256 infection remains poorly understood. Methods to alter the gut microbiota in the form of fecal microbiome 257 transplantation present an experimental tool that has been found to be safe and effective for the reversion of the 258 dysbiotic inflammatory condition of recurrent Clostridium difficile infection. Here, we present evidence that a single 259 introduction of fecal microbiome transplantation via colonoscopy can result in a modest degree of microbial 260 engraftment into HIV-infected, ART-suppressed recipients. Within recipients, specific taxa that trended towards 261 relative abundances found in the microbiota of the donors included Faecalibacterium, Rikenellaceae, and 262
Erysipelotrichaceae. Though a statistically significant shift in overall community composition to donor profiles was 263 observed in recipients following FMT, shifts in individual taxa were not significant after false discovery rate 264 correction, likely due to the inter-individual heterogeneity as well as the very small number of subjects in this study. 265
Furthermore, the immune profile was largely unchanged post-FMT and the nominal decrease in PD-1 expression on 266 CD8 T cells in the context of multiple immune markers is likely attributable to false discovery. 267
268
While microbial engraftment was measurable in our study, the degree of engraftment did not resemble that observed in 269 the treatment of recurrent Clostridium difficile infection (CDI), and was not seen in all subjects. In the setting of CDI, 270 engraftment of donor stool was found to be significantly greater in magnitude than that in our HIV-infected subjects. A 271 putative explanation for the modest engraftment in our study could be the vastly decreased alpha diversity seen in CDI 272 as compared to healthy and HIV-infected subjects. A prominent macroecological phenomenon is "resilience in 273 diversity," in which a diverse community (defined by the richness and evenness of component member distribution) 274 has greater capacity to restore its microbial composition after stress than one that is less ecologically diverse.
[39] Thus, 275 the uniform and phylogenetically restricted community present during recurrent CDI may be susceptible to 276
more complete engraftment after FMT is that patients with recurrent CDI are invariably treated with antibiotics prior to 278 FMT, [18, 40] and such antibiotic conditioning will destabilize the existing microbial community, promoting 279 engraftment of another community. Indeed, the subject that experienced greatest engraftment by the two metrics used 280 herein also had the greatest magnitude of microbiome change in the two time points before FMT, suggesting the 281
destabilize a microbial community will inform future interventions that attempt to introduce a consortium of microbes 289 into the gastrointestinal tract. 290
291
We nevertheless observed changes in abundance of several taxa that have been previously reported to be altered in 292 abundance in HIV-infected subjects as compared to healthy controls, including Faecalibacterium and Rikenellaceae, 293 which are depleted in HIV, and Erysipelotrichaceae, which have been observed as being enriched in HIV[6-10, 45, 294
46]. Notably, Erysipelotrichaceae exhibited an apparent modest depletion after FMT and Faecalibacterium and 295
Rikenellaceae were increased after FMT in our pilot study. Intriguingly, the only subject not to exhibit an increase in 296 further information about the safety of this procedure. Several individuals who participated in our study experienced 320 longstanding and idiopathic chronic loose stools. Anecdotally, several of these participants reported that they felt FMT 321 improved the odor of their stool, improved stool form on the Bristol-Stool scale, and would repeat the procedure again 322 because of the subjective health benefits. 323
324
In summary, FMT was well tolerated in ART-treated HIV-infected individuals. Engraftment was detectable though 325 modest, and appeared to be limited to specific bacterial taxa. In light of successful engraftment during CDI, a protocol 326 mimicking CDI treatment, where antibiotic conditioning occurs prior to FMT, would appear to be warranted. Given 327 the association between specific microbial taxa and systemic inflammation, efforts to enhance engraftment and 328 displace pro-inflammatory microbes may lead to reduction in systemic inflammation, thereby reducing excess 329 morbidity and mortality observed during chronic HIV-infection. and HIV-infected recipient microbiota community dynamics pre-and post-FMT was generated using the Unweighted 466 Unifrac distance metric. After FMT, recipient microbiota profiles remain distinct from the donors. Points outlined in 467 black are post-FMT time points, and shapes of recipient points reflect which donor material was infused by FMT 468 (Donor 01, circles; Donor 37, triangles), while control subjects that received only bowel lavage over the same time 469 period are shown as squares. Lines connect subject sample time points in a temporally linear fashion. B) Unweighted 470
UniFrac distances were calculated as in Figure 2 between each recipient stool microbiota profile time point and its 471 respective donor, using data in the current study for HIV-infected subjects and the study by Weingarden et al. for CDI 472 subjects. C) Alpha diversity was calculated using the Faith's Phylogenetic Diversity metric for each sample in each 473 category shown. D) PCoA plot of data from recurrent CDI subjects given FMT by Khoruts et al.
[24] reveals that CDI 474 subjects differ greatly from donor samples pre-FMT and cluster closely with donor samples post-FMT. E) PCoA plot 475 of data from recurrent CDI subjects given FMT [24] and samples from the current study in HIV-infected subjects 476
HIV-infected subjects as quantified discretely in panel B. 478 
